Department of Orthopaedic Surgery, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan.
Department of Orthopaedic Medical Engineering, Osaka University Graduate School of Medicine, Yamada-oka, Suita, Osaka, 565-0871, Japan.
J Bone Miner Metab. 2020 Sep;38(5):678-686. doi: 10.1007/s00774-020-01096-z. Epub 2020 Mar 31.
The aim of this study was to investigate the effect of bisphosphonates on preventing osteoporotic hip fracture in patients with or without prior major osteoporotic fracture. Randomized controlled trials (RCTs) and observational studies (OSs) based on electronic health records were used to assess bisphosphonate efficacy and were searched using PubMed, Scopus, and the Cochrane Library databases. Eight RCT studies and 14 OSs were extracted from the studies and quantitatively combined by random-effects meta-analysis. The odds ratio (OR) for all hip fractures in RCTs of 0.66, with a 95% confidence interval (CI) of 0.55-0.79, was lower than that in the OSs (OR 0.83; CI 0.74-0.94). The OR in patients with prior fracture was significantly reduced by bisphosphonates in both RCTs and OSs. Conversely, significant fracture reduction was not apparent in patients without prior fracture. A moderate relationship between prior major fracture rates and OR in hip fractures was defined. In patients with an average age of over 80 years, similar results were confirmed. In this meta-analysis, the efficacy of bisphosphonates was significant in patients with prior major fracture, recommending to prescribe for such patients. Their effect in patients without prior fracture, in contrast, remains unclear.
本研究旨在探讨双膦酸盐对预防有或无既往主要骨质疏松性骨折患者的骨质疏松性髋部骨折的影响。使用电子病历的随机对照试验 (RCT) 和观察性研究 (OS) 来评估双膦酸盐的疗效,并使用 PubMed、Scopus 和 Cochrane 图书馆数据库进行检索。从研究中提取了 8 项 RCT 研究和 14 项 OS 研究,并通过随机效应荟萃分析进行定量合并。RCT 中所有髋部骨折的优势比 (OR) 为 0.66,95%置信区间 (CI) 为 0.55-0.79,低于 OS 的 OR(0.83;CI 0.74-0.94)。既往骨折患者的 OR 经双膦酸盐治疗明显降低,无论是在 RCT 还是 OS 中。相反,在无既往骨折的患者中,骨折减少的效果不明显。确定了既往主要骨折发生率与髋部骨折 OR 之间的中度关系。在平均年龄超过 80 岁的患者中,也证实了类似的结果。在这项荟萃分析中,双膦酸盐在既往有主要骨折的患者中疗效显著,建议为这类患者开处方。相反,它们对无既往骨折患者的效果尚不清楚。